BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement 2020;16:541-51. [PMID: 31944580 DOI: 10.1002/alz.12035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ahnaou A, Drinkenburg WHIM. Sleep, neuronal hyperexcitability, inflammation and neurodegeneration: Does early chronic short sleep trigger and is it the key to overcoming Alzheimer's disease? Neurosci Biobehav Rev 2021;129:157-79. [PMID: 34214513 DOI: 10.1016/j.neubiorev.2021.06.039] [Reference Citation Analysis]
3 Webster L, Martin A, Livingston G. The minimum clinically important difference on the sleep disorders inventory for people with dementia. Int J Geriatr Psychiatry 2020;35:1418-23. [PMID: 32725642 DOI: 10.1002/gps.5384] [Reference Citation Analysis]
4 Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1063-78. [DOI: 10.1080/17425255.2020.1817380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
5 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
6 Harris SS, Schwerd-Kleine T, Lee BI, Busche MA. The Reciprocal Interaction Between Sleep and Alzheimer's Disease. Adv Exp Med Biol 2021;1344:169-88. [PMID: 34773232 DOI: 10.1007/978-3-030-81147-1_10] [Reference Citation Analysis]
7 Cummings J. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease. J Neuropsychiatry Clin Neurosci 2021;33:3-13. [PMID: 33108950 DOI: 10.1176/appi.neuropsych.20060152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Jagirdar R, Fu CH, Park J, Corbett BF, Seibt FM, Beierlein M, Chin J. Restoring activity in the thalamic reticular nucleus improves sleep architecture and reduces Aβ accumulation in mice. Sci Transl Med 2021;13:eabh4284. [PMID: 34731016 DOI: 10.1126/scitranslmed.abh4284] [Reference Citation Analysis]
9 Toljan K, Homolak J. Circadian changes in Alzheimer's disease: Neurobiology, clinical problems, and therapeutic opportunities. Handb Clin Neurol 2021;179:285-300. [PMID: 34225969 DOI: 10.1016/B978-0-12-819975-6.00018-2] [Reference Citation Analysis]
10 Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. Mol Neurodegener 2021;16:2. [PMID: 33441154 DOI: 10.1186/s13024-021-00424-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
11 Liguori C, Spanetta M, Romoli M, Placidi F, Nardi Cesarini E, Mercuri NB, Costa C. Sleep disorders and late-onset epilepsy of unknown origin: Understanding new trajectories to brain amyloidopathy. Mech Ageing Dev 2021;194:111434. [PMID: 33444630 DOI: 10.1016/j.mad.2021.111434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Chiu HY, Lee HC, Liu JW, Hua SJ, Chen PY, Tsai PS, Tu YK. Comparative efficacy and safety of hypnotics for insomnia in older adults: a systematic review and network meta-analysis. Sleep 2021;44:zsaa260. [PMID: 33249496 DOI: 10.1093/sleep/zsaa260] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Voysey ZJ, Barker RA, Lazar AS. The Treatment of Sleep Dysfunction in Neurodegenerative Disorders. Neurotherapeutics 2021;18:202-16. [PMID: 33179197 DOI: 10.1007/s13311-020-00959-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Earl DC, Van Tyle KM. New pharmacologic agents for insomnia and hypersomnia. Curr Opin Pulm Med 2020;26:629-33. [PMID: 32890017 DOI: 10.1097/MCP.0000000000000722] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhang F, Zhong RJ, Cheng C, Li S, Le WD. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease. Acta Pharmacol Sin 2021;42:1382-9. [PMID: 33268824 DOI: 10.1038/s41401-020-00565-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
16 Ikeda S, Azuma M, Fujimoto K, Shibahara H, Inoue S, Moline M, Ishii M, Mishima K. Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents. Psychol Med 2022;:1-13. [PMID: 35506334 DOI: 10.1017/S0033291722000356] [Reference Citation Analysis]
17 Xue T, Wu X, Chen S, Yang Y, Yan Z, Song Z, Zhang W, Zhang J, Chen Z, Wang Z. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. Sleep Med Rev 2021;61:101573. [PMID: 34902823 DOI: 10.1016/j.smrv.2021.101573] [Reference Citation Analysis]
18 Mota IFL, de Lima LS, Santana BM, Gobbo GAM, Bicca JVML, Azevedo JRM, Veras LG, Taveira RAA, Pinheiro GB, Mortari MR. Alzheimer's Disease: Innovative Therapeutic Approaches Based on Peptides and Nanoparticles. Neuroscientist 2021;:10738584211016409. [PMID: 34018874 DOI: 10.1177/10738584211016409] [Reference Citation Analysis]
19 Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y) 2021;7:e12179. [PMID: 34095440 DOI: 10.1002/trc2.12179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Gao F, Liu T, Tuo M, Chi S. The role of orexin in Alzheimer disease: From sleep-wake disturbance to therapeutic target. Neurosci Lett 2021;765:136247. [PMID: 34530113 DOI: 10.1016/j.neulet.2021.136247] [Reference Citation Analysis]
21 Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat 2021;17:2549-66. [PMID: 34393484 DOI: 10.2147/NDT.S297504] [Reference Citation Analysis]
22 Cimenser A, Hempel E, Travers T, Strozewski N, Martin K, Malchano Z, Hajós M. Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer's Disease Patients. Front Syst Neurosci 2021;15:746859. [PMID: 34630050 DOI: 10.3389/fnsys.2021.746859] [Reference Citation Analysis]
23 Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y) 2020;6:e12050. [PMID: 32695874 DOI: 10.1002/trc2.12050] [Cited by in Crossref: 66] [Cited by in F6Publishing: 79] [Article Influence: 33.0] [Reference Citation Analysis]
24 Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement 2020;16:541-51. [PMID: 31944580 DOI: 10.1002/alz.12035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
25 Benca R, Herring WJ, Khandker R, Qureshi Z. Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer's Disease: A Structured Literature Review. J Alzheimers Dis 2022. [PMID: 35001893 DOI: 10.3233/JAD-215324] [Reference Citation Analysis]
26 McCleery J, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev 2020;11:CD009178. [PMID: 33189083 DOI: 10.1002/14651858.CD009178.pub4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
27 Subramanian S, Ravichandran M. Orexin receptors: Targets and applications. Fundam Clin Pharmacol 2021. [PMID: 34464995 DOI: 10.1111/fcp.12723] [Reference Citation Analysis]
28 Roland JP, Bliwise DL. Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer's Disease. Drugs Aging 2021;38:951-66. [PMID: 34569029 DOI: 10.1007/s40266-021-00891-1] [Reference Citation Analysis]
29 Seigneur E, de Lecea L. Hypocretin (Orexin) Replacement Therapies. Medicine in Drug Discovery 2020;8:100070. [DOI: 10.1016/j.medidd.2020.100070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Treu SP, Plante DT. Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis. Sleep Med 2021;85:230-8. [PMID: 34364094 DOI: 10.1016/j.sleep.2021.07.007] [Reference Citation Analysis]
31 Svetnik V, Wang TC, Ceesay P, Snyder E, Ceren O, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D, Herring WJ. Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease. J Sleep Res 2021;:e13328. [PMID: 34340251 DOI: 10.1111/jsr.13328] [Reference Citation Analysis]
32 Sunkaria A, Bhardwaj S. Sleep Disturbance and Alzheimer's Disease: The Glial Connection. Neurochem Res 2022. [PMID: 35303225 DOI: 10.1007/s11064-022-03578-0] [Reference Citation Analysis]
33 Berteotti C, Liguori C, Pace M. Dysregulation of the orexin/hypocretin system is not limited to narcolepsy but has far-reaching implications for neurological disorders. Eur J Neurosci 2021;53:1136-54. [PMID: 33290595 DOI: 10.1111/ejn.15077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Blackman J, Swirski M, Clynes J, Harding S, Leng Y, Coulthard E. Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review. J Sleep Res 2021;30:e13229. [PMID: 33289311 DOI: 10.1111/jsr.13229] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
35 Kent BA, Feldman HH, Nygaard HB. Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer's disease. Prog Neurobiol 2021;197:101902. [PMID: 32877742 DOI: 10.1016/j.pneurobio.2020.101902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]